PL443854A1 - Epitop pochodzący z białka N wirusa SARS-CoV-2, zawierający go antygen, ich zastosowania i sposób wykrywania choroby wywoływanej przez koronawirusa - Google Patents

Epitop pochodzący z białka N wirusa SARS-CoV-2, zawierający go antygen, ich zastosowania i sposób wykrywania choroby wywoływanej przez koronawirusa

Info

Publication number
PL443854A1
PL443854A1 PL443854A PL44385423A PL443854A1 PL 443854 A1 PL443854 A1 PL 443854A1 PL 443854 A PL443854 A PL 443854A PL 44385423 A PL44385423 A PL 44385423A PL 443854 A1 PL443854 A1 PL 443854A1
Authority
PL
Poland
Prior art keywords
cov
sars
coronavirus
disease caused
virus
Prior art date
Application number
PL443854A
Other languages
English (en)
Inventor
Agnieszka RAZIM
Andrzej Gamian
Sabina GÓRSKA
Original Assignee
Instytut Immunologii I Terapii Doświadczalnej Polskiej Akademii Nauk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Immunologii I Terapii Doświadczalnej Polskiej Akademii Nauk filed Critical Instytut Immunologii I Terapii Doświadczalnej Polskiej Akademii Nauk
Priority to PL443854A priority Critical patent/PL443854A1/pl
Priority to EP24721787.0A priority patent/EP4669349A2/en
Priority to PCT/PL2024/050015 priority patent/WO2024177525A2/en
Publication of PL443854A1 publication Critical patent/PL443854A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

W zgłoszeniu ujawniono epitop pochodzący z białka N wirusa SARS-CoV-2, antygen szczepionkowy specyficzny dla SARS-CoV-2, zawierający taki epitop nadający się do zastosowania w leczeniu lub zapobieganiu choroby wywoływanej przez koronawirusa, a także sposób wykrywania choroby wywoływanej przez koronawirusa, w szczególności COVID-19, zwłaszcza o ostrym przebiegu.
PL443854A 2023-02-22 2023-02-22 Epitop pochodzący z białka N wirusa SARS-CoV-2, zawierający go antygen, ich zastosowania i sposób wykrywania choroby wywoływanej przez koronawirusa PL443854A1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL443854A PL443854A1 (pl) 2023-02-22 2023-02-22 Epitop pochodzący z białka N wirusa SARS-CoV-2, zawierający go antygen, ich zastosowania i sposób wykrywania choroby wywoływanej przez koronawirusa
EP24721787.0A EP4669349A2 (en) 2023-02-22 2024-02-22 Epitope from the SARS-CoV-2 N protein, antigen containing the epitope, uses thereof, and method for detecting a disease caused by a coronavirus
PCT/PL2024/050015 WO2024177525A2 (en) 2023-02-22 2024-02-22 An epitope originating from sars-cov-2 n protein, an antigen containing the epitope, uses thereof and a method for detecting disease caused by coronavirus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL443854A PL443854A1 (pl) 2023-02-22 2023-02-22 Epitop pochodzący z białka N wirusa SARS-CoV-2, zawierający go antygen, ich zastosowania i sposób wykrywania choroby wywoływanej przez koronawirusa

Publications (1)

Publication Number Publication Date
PL443854A1 true PL443854A1 (pl) 2024-08-26

Family

ID=90880435

Family Applications (1)

Application Number Title Priority Date Filing Date
PL443854A PL443854A1 (pl) 2023-02-22 2023-02-22 Epitop pochodzący z białka N wirusa SARS-CoV-2, zawierający go antygen, ich zastosowania i sposób wykrywania choroby wywoływanej przez koronawirusa

Country Status (3)

Country Link
EP (1) EP4669349A2 (pl)
PL (1) PL443854A1 (pl)
WO (1) WO2024177525A2 (pl)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113717258A (zh) * 2021-09-03 2021-11-30 郑州安图生物工程股份有限公司 一种SARS-CoV-2感染细胞免疫检测的抗原多肽组合物及其应用、试剂盒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296617A (en) * 2020-03-20 2022-11-01 Biontech Us Inc Vaccines against the corona virus and methods of use
US20230213516A1 (en) * 2020-04-24 2023-07-06 Quidel Corporation Immunoassays for detection of immunoglobulins against sars cov-2 and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113717258A (zh) * 2021-09-03 2021-11-30 郑州安图生物工程股份有限公司 一种SARS-CoV-2感染细胞免疫检测的抗原多肽组合物及其应用、试剂盒

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
E. MARTYNOVA ET AL.: "Front Immunol. 2022 Mar 21;13:830715", "IMMUNOGENIC SARS-COV-2 S AND N PROTEIN PEPTIDE AND CYTOKINE COMBINATIONS AS BIOMARKERS FOR EARLY PREDICTION OF FATAL COVID-19" *

Also Published As

Publication number Publication date
WO2024177525A3 (en) 2024-09-19
WO2024177525A2 (en) 2024-08-29
EP4669349A2 (en) 2025-12-31

Similar Documents

Publication Publication Date Title
BR102021005055A2 (pt) detecção de anticorpos para sarsr-cov
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
CY1124488T1 (el) Απελευθερωση πρωτεϊνης που βασιζεται σε εξασθενημενης λοιμογονικοτητας βακτηριδια
BR112022018949A2 (pt) Anticorpos monoclonais humanos para síndrome respiratória aguda grave coronavírus 2 (sars-cov-2)
TW200512457A (en) Method of diagnosing SARS corona virus infection
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
CY1113190T1 (el) Μεθοδος αγωγης της αιμολυτικης νοσου
MX340547B (es) Equipos de prueba de diagnostico.
BR112017001339A2 (pt) método, pasta de cimento e sistema
CY1111521T1 (el) Λοιμογονος συστηματικος καλυκοϊος αιλουροειδων
MX2022013296A (es) Dispositivo de flujo lateral para deteccion anticuerpos neutralizantes contra sars-cov-2.
ATE549031T1 (de) Impfstoffzusammensetzung zur prävention von cmv- infektionen
MX2023001160A (es) Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo.
EA202090587A1 (ru) Способ получения сплит-вакцины с на гриппа
EP3940386A4 (en) ANALYTICAL COLLECTION DEVICE AND ANALYTICAL COLLECTION METHOD AND ANALYTICAL INSPECTION SYSTEM WITH USE THEREOF
WO2015143194A3 (en) Immunogenetic restriction on elicitation of antibodies
JOP20210279A1 (ar) طرق لعلاج حالات مصابة بالتهاب المفاصل الصدفي
BR112023002234A2 (pt) Anticorpos sars-cov-2 para tratamento e prevenção de covid-19
PL443854A1 (pl) Epitop pochodzący z białka N wirusa SARS-CoV-2, zawierający go antygen, ich zastosowania i sposób wykrywania choroby wywoływanej przez koronawirusa
MX2022003396A (es) Uso de inhibidores de dkk-1 para tratar el cancer.
CL2009000287A1 (es) Composicion que comprende un alfavirus salmonideo (sav) inactivado y al menos un componente seleccionado de una bacteria muerta/inactivada, otro virus inactivado, un hongo, un parasito y un material antigenico derivado de la bacteria, virus, hongo o parasito anterior; metodo para elaborar la composicion y uso del sav.
CR20240255A (es) Anticuerpo anti-trems y usos del mismo
WO2022069704A3 (de) Immundiagnostische mittel und verfahren für den nachweis und die differenzierung von coronavirus-infektionen
BR132018069012E2 (pt) uso de anticorpos policlonais humanos ou fragmentos destes, e, composição farmacêutica
CL2022002727A1 (es) Anticuerpo anti-cd47 y usos del mismo